Core Viewpoint - The company, 宜明昂科-B (01541.HK), has announced a placement agreement with Credit Suisse to issue 24.2 million new H-shares at a price of HKD 14.50 per share, representing a discount of approximately 12.97% from the last closing price of HKD 16.66 [1] Group 1: Placement Details - The placement will involve the issuance of 24.2 million new H-shares, which accounts for about 5.94% of the company's total issued share capital and approximately 6.11% of the total issued H-shares as of the announcement date [1] - The estimated total gross proceeds from the placement are approximately HKD 350.9 million, with net proceeds expected to be around HKD 345.1 million [1] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated to fund the research and development of IMM2510 and IMM27M for the treatment of solid tumors [1] - About 20% of the net proceeds will be used to fund the research and development of IMM01 (Tideglusib) [1] - Approximately 10% will be allocated for the research and development of IMM0306, while around 30% will be used to supplement the company's working capital and for general corporate purposes [1]
宜明昂科-B(01541.HK)拟配售2420万股总筹3.51亿港元 加码肿瘤药物研发